

# Gary W Falk

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5814225/gary-w-falk-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

223  
papers

13,502  
citations

56  
h-index

113  
g-index

275  
ext. papers

15,965  
ext. citations

5.4  
avg, IF

6.13  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 223 | Eosinophilic esophagitis: updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 128, 3-20.e6; quiz 21-2  | 11.5 | 1502      |
| 222 | Radiofrequency ablation in Barrett's esophagus with dysplasia. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2277-88  | 59.2 | 1097      |
| 221 | ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 30-50; quiz 51  | 0.7  | 928       |
| 220 | A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. <i>Gastroenterology</i> , <b>2004</b> , 127, 310-30   | 13.3 | 521       |
| 219 | Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. <i>Gastroenterology</i> , <b>2011</b> , 141, 460-8   | 13.3 | 367       |
| 218 | Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , <b>2018</b> , 155, 1022-1033.e10   | 13.3 | 367       |
| 217 | Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 566-72  | 6.9  | 334       |
| 216 | The seroprevalence of cagA-positive <i>Helicobacter pylori</i> strains in the spectrum of gastroesophageal reflux disease. <i>Gastroenterology</i> , <b>1998</b> , 115, 50-7  | 13.3 | 314       |
| 215 | Barrett's esophagus. <i>Gastroenterology</i> , <b>2002</b> , 122, 1569-91   | 13.3 | 311       |
| 214 | Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. <i>Gastroenterology</i> , <b>2012</b> , 143, 336-46  | 13.3 | 305       |
| 213 | Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. <i>Nature Medicine</i> , <b>2013</b> , 19, 1005-13   | 50.5 | 271       |
| 212 | Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. <i>Gastrointestinal Endoscopy</i> , <b>1999</b> , 49, 170-6   | 5.2  | 262       |
| 211 | Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and <i>H. pylori</i> infection. <i>Gastroenterology</i> , <b>1998</b> , 114, 633-9  | 13.3 | 238       |
| 210 | The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland clinic Barrett's esophagus registry. <i>American Journal of Gastroenterology</i> , <b>1999</b> , 94, 2037-2042                          | 0.7  | 206       |
| 209 | The gastric cardia: fact or fiction?. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 921-4   | 0.7  | 204       |
| 208 | Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. <i>Gastroenterology</i> , <b>2011</b> , 141, 1179-86, 1186.e1   | 13.3 | 198       |
| 207 | Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. <i>Gastroenterology</i> , <b>2013</b> , 145, 79-86.e1 | 13.3 | 189       |

|     |   |      |     |
|-----|---|------|-----|
| 206 | Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 220-7; quiz e26                              | 6.9  | 174 |
| 205 | In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). <i>Gastrointestinal Endoscopy</i> , <b>2014</b> , 79, 211-21                | 5.2  | 153 |
| 204 | An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 70, 635-44                   | 5.2  | 142 |
| 203 | CagA-positive strains of <i>Helicobacter pylori</i> may protect against Barrett's esophagus. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 2206-11  | 0.7  | 142 |
| 202 | Superficial adenocarcinoma of the esophagus. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2001</b> , 122, 1077-90   | 1.5  | 136 |
| 201 | Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. <i>Gastroenterology</i> , <b>2020</b> , 158, 111-122.e10  | 13.3 | 135 |
| 200 | Practice patterns for surveillance of Barrett's esophagus in the united states. <i>Gastrointestinal Endoscopy</i> , <b>2000</b> , 52, 197-203   | 5.2  | 123 |
| 199 | The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on imaging in Barrett's Esophagus. <i>Gastrointestinal Endoscopy</i> , <b>2012</b> , 76, 252-4           | 5.2  | 120 |
| 198 | Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 776-786.e5                       | 13.3 | 114 |
| 197 | The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. <i>American Journal of Gastroenterology</i> , <b>1999</b> , 94, 2037-42                            | 0.7  | 112 |
| 196 | Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. <i>Gastroenterology</i> , <b>2012</b> , 143, 564-566.e1   | 13.3 | 109 |
| 195 | p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 2508-13                               | 0.7  | 109 |
| 194 | Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. <i>Gastroenterology</i> , <b>2000</b> , 119, 683-90  | 13.3 | 102 |
| 193 | Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 1430-6                        | 6.9  | 99  |
| 192 | Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 1668-73                            | 4    | 93  |
| 191 | BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 662-82; quiz 683 | 0.7  | 92  |
| 190 | T-helper 2 cytokines, transforming growth factor $\beta$ , and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis. <i>Gastroenterology</i> , <b>2014</b> , 146, 1266-77.e13  | 13.3 | 92  |
| 189 | Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. <i>Gastrointestinal Endoscopy</i> , <b>1994</b> , 40, 207-12  | 5.2  | 91  |

|     |  |      |    |
|-----|--|------|----|
| 188 | Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. <i>Digestive Diseases and Sciences</i> , <b>2003</b> , 48, 1537-41  | 4    | 81 |
| 187 | The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 653-8; quiz 606                           | 6.9  | 79 |
| 186 | Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. <i>American Journal of Physiology - Renal Physiology</i> , <b>2010</b> , 298, G571-81  | 5.1  | 78 |
| 185 | Risk factors for esophageal cancer development. <i>Surgical Oncology Clinics of North America</i> , <b>2009</b> , 18, 469-85   | 2.7  | 78 |
| 184 | Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. <i>American Journal of Gastroenterology</i> , <b>1998</b> , 93, 1800-2  | 0.7  | 74 |
| 183 | Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. <i>Gastrointestinal Endoscopy</i> , <b>2018</b> , 87, 348-355   | 5.2  | 71 |
| 182 | Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. <i>Gastroenterology</i> , <b>2018</b> , 154, 1282-1289.e2  | 13.3 | 69 |
| 181 | Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. <i>Gastroenterology</i> , <b>2013</b> , 145, 548-53.e1  | 13.3 | 69 |
| 180 | Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. <i>Cancer</i> , <b>2006</b> , 107, 2160-6   | 6.4  | 69 |
| 179 | Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial. <i>Gastroenterology</i> , <b>2017</b> , 153, 681-688.e2                        | 13.3 | 67 |
| 178 | Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 302-11   | 0.7  | 66 |
| 177 | Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia. <i>Gastroenterology</i> , <b>2015</b> , 149, 567-76.e3; quiz e13-4   | 13.3 | 65 |
| 176 | The role of allergy evaluation in adults with eosinophilic esophagitis. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, 22-7   | 3    | 65 |
| 175 | Observer variation and reproducibility of endoscopic ultrasonography. <i>Gastrointestinal Endoscopy</i> , <b>1995</b> , 41, 115-20   | 5.2  | 65 |
| 174 | Association of insulin and insulin-like growth factors with Barrett's oesophagus. <i>Gut</i> , <b>2012</b> , 61, 665-72  | 19.2 | 63 |
| 173 | A coxib a day won't keep the doctor away. <i>Lancet, The</i> , <b>2004</b> , 364, 639-40   | 40   | 63 |
| 172 | Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. <i>Gastroenterology</i> , <b>2015</b> , 149, 1599-606 | 13.3 | 61 |
| 171 | BMP-driven NRF2 activation in esophageal basal cell differentiation and eosinophilic esophagitis. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 1557-68  | 15.9 | 61 |

|     |   |      |    |
|-----|---|------|----|
| 170 | Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2187-93   | 0.7  | 60 |
| 169 | Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 477-488   | 18.8 | 57 |
| 168 | Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1964-71   | 0.7  | 56 |
| 167 | Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. <i>Modern Pathology</i> , <b>2004</b> , 17, 588-96   | 9.8  | 53 |
| 166 | Role of Helicobacter pylori cagA(+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. <i>International Journal of Cancer</i> , <b>1999</b> , 82, 520-4   | 7.5  | 52 |
| 165 | A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. <i>Gastroenterology</i> , <b>2012</b> , 143, 917-26.e1  | 13.3 | 50 |
| 164 | Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 495-503.e8  | 6.9  | 48 |
| 163 | Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. <i>Gastrointestinal Endoscopy</i> , <b>2013</b> , 77, 190-9   | 5.2  | 46 |
| 162 | Esophageal manometry: assessment of interpreter consistency. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 218-24  | 6.9  | 44 |
| 161 | AGA Institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. <i>Gastroenterology</i> , <b>2006</b> , 131, 1315-36   | 13.3 | 44 |
| 160 | Is FDG-PET indicated for superficial esophageal cancer?. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2007</b> , 31, 791-6   | 3    | 43 |
| 159 | The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2018</b> , 5, 333-352  | 7.9  | 41 |
| 158 | Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy. <i>Gastroenterology</i> , <b>2017</b> , 152, 987-992   | 13.3 | 40 |
| 157 | Assessment of familiarity, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1913-21  | 0.7  | 40 |
| 156 | p53 Immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>1994</b> , 108, 1132-1137  | 1.5  | 40 |
| 155 | Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 984-994 | 0.7  | 38 |
| 154 | The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on peroral endoscopic myotomy. <i>Gastrointestinal Endoscopy</i> , <b>2015</b> , 81, 1087-100.e1   | 5.2  | 37 |
| 153 | Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , <b>2014</b> , 80, 71-7   | 5.2  | 37 |

|     |   |      |    |
|-----|---|------|----|
| 152 | Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 1340-5   | 0.7  | 37 |
| 151 | Location, location, location: does early cancer in Barrett's esophagus have a preference?. <i>Gastrointestinal Endoscopy</i> , <b>2013</b> , 78, 462-7  | 5.2  | 36 |
| 150 | A segregation analysis of Barrett's esophagus and associated adenocarcinomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 666-74   | 4    | 36 |
| 149 | Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 665-72.e1-4   | 6.9  | 35 |
| 148 | Autofluorescence endoscopy. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2009</b> , 19, 209-20   | 3.3  | 35 |
| 147 | Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 864-868   | 6.9  | 34 |
| 146 | Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 1089-94   | 6.9  | 33 |
| 145 | Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>Gastrointestinal Endoscopy</i> , <b>2017</b> , 86, 1-17.e3 | 5.2  | 32 |
| 144 | Pathogenesis of gastroesophageal reflux and Barrett esophagus. <i>Mayo Clinic Proceedings</i> , <b>2001</b> , 76, 226-34  | 3.4  | 31 |
| 143 | Fluorescence in situ hybridization of cytologic specimens from Barrett's esophagus: a pilot feasibility study. <i>Gastrointestinal Endoscopy</i> , <b>2004</b> , 60, 280-4  | 5.2  | 28 |
| 142 | A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 958-68   | 4    | 28 |
| 141 | Autophagy mediates epithelial cytoprotection in eosinophilic oesophagitis. <i>Gut</i> , <b>2017</b> , 66, 1197-1207   | 19.2 | 27 |
| 140 | Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , <b>2015</b> , 81, 1158-66.e1-4                            | 5.2  | 27 |
| 139 | Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet?. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 1011-1014   | 11.5 | 27 |
| 138 | Esophageal epithelial cells acquire functional characteristics of activated myofibroblasts after undergoing an epithelial to mesenchymal transition. <i>Experimental Cell Research</i> , <b>2015</b> , 330, 102-10  | 4.2  | 27 |
| 137 | Cryotherapy and Radiofrequency Ablation for Eradication of Barrett's Esophagus with Dysplasia or Intramucosal Cancer. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 1311-1319  | 4    | 26 |
| 136 | Endoscopic surveillance of Barrett's esophagus: risk stratification and cancer risk. <i>Gastrointestinal Endoscopy</i> , <b>1999</b> , 49, S29-34   | 5.2  | 26 |
| 135 | Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 130-138.e1   | 11.5 | 25 |

|     |  |      |    |
|-----|--|------|----|
| 134 | Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1032-1048 | 0.7  | 24 |
| 133 | Clinical Guidelines Update on the Diagnosis and Management of Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 2122-2128  | 4    | 24 |
| 132 | Modeling inflammation and oxidative stress in gastrointestinal disease development using novel organotypic culture systems. <i>Stem Cell Research and Therapy</i> , <b>2013</b> , 4 Suppl 1, S5  | 8.3  | 24 |
| 131 | Variation in age at cancer diagnosis in familial versus nonfamilial Barrett's esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 376-83   | 4    | 24 |
| 130 | Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma. <i>Gastroenterology</i> , <b>2020</b> , 159, 575-590   | 13.3 | 23 |
| 129 | Barrett's esophagus: prevalence-incidence and etiology-origins. <i>Annals of the New York Academy of Sciences</i> , <b>2011</b> , 1232, 1-17   | 6.5  | 23 |
| 128 | A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2017</b> , 26, 240-248  | 4    | 22 |
| 127 | Esophageal cancer: The latest on chemoprevention and state of the art therapies. <i>Pharmacological Research</i> , <b>2016</b> , 113, 236-244  | 10.2 | 22 |
| 126 | Management of nondysplastic Barrett's esophagus: where are we now?. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 805-8   | 0.7  | 21 |
| 125 | Virtual Dysphagia Evaluation: Practical Guidelines for Dysphagia Management in the Context of the COVID-19 Pandemic. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2020</b> , 163, 455-458  | 5.5  | 21 |
| 124 | Eosinophilic Esophagitis-Associated Chemical and Mechanical Microenvironment Shapes Esophageal Fibroblast Behavior. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2016</b> , 63, 200-9   | 2.8  | 21 |
| 123 | Fibrotic eosinophilic esophagitis might reflect epithelial lysyl oxidase induction by fibroblast-derived TNF- $\alpha$ . <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 171-182  | 11.5 | 19 |
| 122 | Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort study. <i>Endoscopy</i> , <b>2015</b> , 47, 669-74   | 3.4  | 19 |
| 121 | Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 255-269   | 11.5 | 19 |
| 120 | Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. <i>Gastrointestinal Endoscopy</i> , <b>2020</b> , 92, 31-39.e1   | 5.2  | 18 |
| 119 | Effect of pneumatic dilation on gastroesophageal reflux in achalasia. <i>Digestive Diseases and Sciences</i> , <b>1997</b> , 42, 998-1002  | 4    | 18 |
| 118 | Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>1994</b> , 4, 773-789   | 3.3  | 18 |
| 117 | Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Translational Science of Rare Diseases</i> , <b>2017</b> , 2, 141-155  | 3.3  | 17 |

|     |  |      |    |
|-----|--|------|----|
| 116 | Extent of low-grade dysplasia in Barrett's esophagus: is it useful for risk stratification?. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 494-6  | 0.7  | 17 |
| 115 | Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2024-2035 | 4    | 17 |
| 114 | Associations of Serum Adiponectin and Leptin With Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 2265-72   | 6.9  | 16 |
| 113 | Effect of ozone and nitrogen dioxide on the agglutination of rat alveolar macrophages by concanavalin A. <i>Life Sciences</i> , <b>1977</b> , 21, 1637-44  | 6.8  | 16 |
| 112 | Eosinophilic esophagitis: an increasingly recognized cause of dysphagia, food impaction, and refractory heartburn. <i>Cleveland Clinic Journal of Medicine</i> , <b>2008</b> , 75, 623-6, 629-33   | 2.8  | 16 |
| 111 | Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 1629-1640.e4   | 11.5 | 15 |
| 110 | Poor discriminatory function for endoscopic skills on a computer-based simulator. <i>Gastrointestinal Endoscopy</i> , <b>2012</b> , 76, 993-1002   | 5.2  | 15 |
| 109 | Cytology in Barrett's esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2003</b> , 13, 335-48   | 3.3  | 15 |
| 108 | Role of barium esophagography in evaluating dysphagia. <i>Cleveland Clinic Journal of Medicine</i> , <b>2009</b> , 76, 105-11  | 2.8  | 15 |
| 107 | Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. <i>Molecular Carcinogenesis</i> , <b>2016</b> , 55, 1526-1541   | 5    | 15 |
| 106 | AGA Institute medical position statement on the use of endoscopic therapy for gastroesophageal reflux disease. <i>Gastroenterology</i> , <b>2006</b> , 131, 1313-4   | 13.3 | 14 |
| 105 | Low Yield of Cross-Sectional Imaging in Patients With Esophagogastric Junction Outflow Obstruction. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1643-1644  | 6.9  | 14 |
| 104 | Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1842-1844                         | 6.9  | 14 |
| 103 | Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.. <i>American Journal of Gastroenterology</i> , <b>2022</b> , 117, 559-587   | 0.7  | 14 |
| 102 | Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 750-759   | 6.1  | 13 |
| 101 | Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems. <i>Experimental Biology and Medicine</i> , <b>2014</b> , 239, 1108-23  | 3.7  | 13 |
| 100 | Subsquamous intestinal metaplasia: implications for endoscopic management of Barrett's esophagus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 220-4  | 6.9  | 13 |
| 99  | Findings of Esophagography for 25 Patients After Peroral Endoscopic Myotomy for Achalasia. <i>American Journal of Roentgenology</i> , <b>2016</b> , 207, 1185-1193   | 5.4  | 13 |



|    |   |      |    |
|----|---|------|----|
| 98 | Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus. <i>Journal of Molecular Diagnostics</i> , <b>2015</b> , 17, 412-9 | 5.1  | 12 |
| 97 | Clinical presentation of eosinophilic esophagitis in adults. <i>Gastroenterology Clinics of North America</i> , <b>2014</b> , 43, 231-42  | 4.4  | 12 |
| 96 | 213 A Randomized, Multicenter, Sham-Controlled Trial of Radiofrequency Ablation (RFA) for Subjects with Barrett's Esophagus (Be) Containing Dysplasia: Interim Results of the Aim Dysplasia Trial. <i>Gastroenterology</i> , <b>2008</b> , 134, A-37  | 13.3 | 12 |
| 95 | Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma. <i>Translational Research</i> , <b>2007</b> , 150, 3-17   | 11   | 12 |
| 94 | Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,   | 6.9  | 12 |
| 93 | Barrett's esophagus: endoscopic diagnosis. <i>Annals of the New York Academy of Sciences</i> , <b>2011</b> , 1232, 53-75  | 7.5  | 11 |
| 92 | Is conventional endoscopic identification of non-erosive reflux disease adequate?. <i>Digestion</i> , <b>2008</b> , 78 Suppl 1, 17-23   | 3.6  | 11 |
| 91 | Unresolved issues in Barrett's esophagus in the new millennium. <i>Digestive Diseases</i> , <b>2000</b> , 18, 27-42   | 3.2  | 11 |
| 90 | Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium. <i>Gastrointestinal Endoscopy</i> , <b>2019</b> , 89, 257-263.e3   | 5.2  | 11 |
| 89 | Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids. <i>Current Protocols in Stem Cell Biology</i> , <b>2020</b> , 53, e109   | 2.8  | 11 |
| 88 | Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , <b>2015</b> , 44, 299-315  | 4.4  | 10 |
| 87 | Achalasia Patients Are at Nutritional Risk Regardless of Presenting Weight Category. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 1243-1249   | 4    | 10 |
| 86 | ATG7 Gene Expression as a Novel Tissue Biomarker in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 151-3  | 0.7  | 10 |
| 85 | An Analysis of the GIQuIC Nationwide Quality Registry Reveals Unnecessary Surveillance Endoscopies in Patients With Normal and Irregular Z-Lines. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1869-1878  | 0.7  | 10 |
| 84 | Proton pump inhibitor-responsive oesophageal eosinophilia: too early to change clinical practice. <i>Gut</i> , <b>2017</b> , 66, 979-980  | 19.2 | 9  |
| 83 | Barrett's oesophagus length is established at the time of initial endoscopy and does not change over time: results from a large multicentre cohort. <i>Gut</i> , <b>2015</b> , 64, 1874-80  | 19.2 | 9  |
| 82 | Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 727-35   | 4    | 9  |
| 81 | Eosinophilic pancreatitis presenting as a pancreatic mass with obstructive jaundice. <i>Gastrointestinal Endoscopy</i> , <b>2006</b> , 63, 525-7  | 5.2  | 9  |

|    |   |      |   |
|----|---|------|---|
| 80 | Progression of Barrett's esophagus to high grade dysplasia and cancer: Preliminary results of the BEST (Barrett's esophagus study) trial. <i>Gastroenterology</i> , <b>2001</b> , 120, A16-A17  | 13.3 | 9 |
| 79 | Persistent Basal Cell Hyperplasia Is Associated With Clinical and Endoscopic Findings in Patients With Histologically Inactive Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1475-1482.e1 | 6.9  | 9 |
| 78 | Motility and GI function studies billing and coding guidelines: a position paper of the American Motility Society. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, 1228-36  | 0.7  | 8 |
| 77 | Barrett's esophagus-is it bad for your health?. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 2622-3   | 0.7  | 8 |
| 76 | Barrett's oesophagus: frequency and prediction of dysplasia and cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2015</b> , 29, 125-38  | 2.5  | 7 |
| 75 | Chemoprevention and Barrett's esophagus: decisions, decisions. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2443-5  | 0.7  | 7 |
| 74 | Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1477-1488.e10                                     | 6.9  | 6 |
| 73 | Modeling Epithelial Homeostasis and Reactive Epithelial Changes in Human and Murine Three-Dimensional Esophageal Organoids. <i>Current Protocols in Stem Cell Biology</i> , <b>2020</b> , 52, e106  | 2.8  | 6 |
| 72 | Evidence for DNA damage checkpoint activation in barrett esophagus. <i>Translational Oncology</i> , <b>2010</b> , 3, 33-42  | 4.9  | 6 |
| 71 | Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia. <i>Oncotarget</i> , <b>2015</b> , 6, 32980-3005   | 3.3  | 6 |
| 70 | High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 2754-2766                                    | 7.5  | 5 |
| 69 | Genomic regions associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184962                                 | 2.7  | 5 |
| 68 | Barrett's esophagus surveillance: When, how often, does it work?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2011</b> , 21, 9-24   | 3.3  | 5 |
| 67 | Radiofrequency ablation of Barrett's esophagus: should everybody get it?. <i>Gastroenterology</i> , <b>2009</b> , 136, 2399-401; discussion 2401-2  | 13.3 | 5 |
| 66 | Obesity and gastroesophageal reflux disease: another piece of the puzzle. <i>Gastroenterology</i> , <b>2008</b> , 134, 1620-2   | 13.3 | 5 |
| 65 | Eosinophilic esophagitis: new insights into an emerging disease. <i>Gastroenterology</i> , <b>2006</b> , 131, 2018-20; discussion 2020  | 13.3 | 5 |
| 64 | Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue. <i>Oncotarget</i> , <b>2019</b> , 10, 3592-3604  | 3.3  | 5 |
| 63 | Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development. <i>EBioMedicine</i> , <b>2019</b> , 49, 145-156  | 8.8  | 5 |

|    |  |       |   |
|----|--|-------|---|
| 62 | Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , <b>2021</b> , 93, 1250-1257.e3             | 5.2   | 5 |
| 61 | Columnar islands in Barrett's esophagus: Do they impact Prague C&M criteria and dysplasia grade?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1598-1603                          | 4     | 4 |
| 60 | Modeling Esophagitis Using Human Three-Dimensional Organotypic Culture System. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 1787-1799   | 5.8   | 4 |
| 59 | Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1143-8  | 0.7   | 4 |
| 58 | 92 Durability of Epithelial Reversion After Radiofrequency Ablation: Follow-up of the AIM Dysplasia Trial. <i>Gastroenterology</i> , <b>2010</b> , 138, S-16-S-17  | 13.3  | 4 |
| 57 | Laryngopharyngeal reflux: beauty is in the eye of the beholder. <i>Gastroenterology</i> , <b>2007</b> , 133, 1379-81   | 13.3  | 4 |
| 56 | Turning an idea into a grant. <i>Gastrointestinal Endoscopy</i> , <b>2006</b> , 64, S11-3  | 5.2   | 4 |
| 55 | Endoscopic surveillance of Barrett's esophagus. <i>Techniques in Gastrointestinal Endoscopy</i> , <b>2000</b> , 2, 186-193   | 4     | 4 |
| 54 | Eosinophilic Esophagitis: A Review. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 1310-1318   | 13.18 | 4 |
| 53 | Low Risk of Progression of Barrett's Esophagus to Neoplasia in Women. <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> , 55, 321-326  | 3     | 4 |
| 52 | High Patient Disease Burden in a Cross-sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2020</b> , 71, 524-529 | 2.8   | 4 |
| 51 | Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas. <i>Molecular Genetics &amp; Genomic Medicine</i> , <b>2016</b> , 4, 407-19   | 2.3   | 4 |
| 50 | Best Practices in Surveillance for Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2021</b> , 31, 59-75   | 3.3   | 4 |
| 49 | Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,  | 11.5  | 4 |
| 48 | Barrett's esophagus: surveillance and reversal. <i>Annals of the New York Academy of Sciences</i> , <b>2011</b> , 1232, 196-209  | 6.5   | 3 |
| 47 | Inhibition of transient lower esophageal sphincter relaxation in GERD: will lesogaberan advance the field?. <i>Gastroenterology</i> , <b>2010</b> , 139, 377-9   | 13.3  | 3 |
| 46 | Why is esophageal adenocarcinoma increasing in incidence?. <i>Abdominal Imaging</i> , <b>1998</b> , 23, 539-42   |       | 3 |
| 45 | Refractory GERD: further insights into the cause of symptoms. <i>Gastroenterology</i> , <b>2008</b> , 135, 1414-5  | 13.3  | 3 |

|    |  |      |   |
|----|--|------|---|
| 44 | Pathogenesis of Gastroesophageal Reflux and Barrett Esophagus. <i>Mayo Clinic Proceedings</i> , <b>2001</b> , 76, 226-234  | 6.4  | 3 |
| 43 | Updated Guidelines for Diagnosing and Managing Barrett Esophagus. <i>Gastroenterology and Hepatology</i> , <b>2016</b> , 12, 449-51  | 0.7  | 3 |
| 42 | Type II achalasia is associated with a comparably favorable outcome following per oral endoscopic myotomy. <i>Ecological Management and Restoration</i> , <b>2021</b> , 34,  | 3    | 3 |
| 41 | Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,   | 6.9  | 3 |
| 40 | Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,   | 6.9  | 3 |
| 39 | Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,                                      | 6.9  | 3 |
| 38 | International consensus recommendations for eosinophilic gastrointestinal disease nomenclature.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2022</b> ,   | 6.9  | 3 |
| 37 | Cutting to the chase: circumferential endoscopic mucosal resection for Barrett's neoplasia. <i>Gut</i> , <b>2010</b> , 59, 1163-4  | 19.2 | 2 |
| 36 | M1104 Predicting High-Grade Dysplasia (HGD) and Esophageal Adenocarcinoma (EAC) in Patients With Non-Dysplastic Barrett's Esophagus (BE): Results From a Large, Multicenter Cohort Study. <i>Gastroenterology</i> , <b>2010</b> , 138, S-333 | 13.3 | 2 |
| 35 | How exactly do i diagnose intestinal metaplasia in Barrett's esophagus?. <i>Gastroenterology</i> , <b>2007</b> , 133, 2060-2; discussion 2062  | 13.3 | 2 |
| 34 | Current Management of Low-Grade Dysplasia in Barrett Esophagus. <i>Gastroenterology and Hepatology</i> , <b>2017</b> , 13, 221-225   | 0.7  | 2 |
| 33 | Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer. <i>Scientific Reports</i> , <b>2021</b> , 11, 21304   | 4.9  | 2 |
| 32 | Gastroesophageal reflux disease. <i>Current Opinion in Gastroenterology</i> , <b>1999</b> , 15, 333-8  | 3    | 2 |
| 31 | 2017 David Sun Lecture: Screening and Surveillance of Barrett's Esophagus: Where Are We Now and What Does the Future Hold?. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 64-70   | 0.7  | 2 |
| 30 | Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , <b>2021</b> ,  | 5.2  | 2 |
| 29 | An Unusual Cause of Abdominal Pain. Appendiceal Intussusception Owing to Cecal Adenocarcinoma. <i>Gastroenterology</i> , <b>2015</b> , 149, e1-2   | 13.3 | 1 |
| 28 | Is the age of diagnosis of esophageal adenocarcinoma getting younger? Analysis at a tertiary care center. <i>Ecological Management and Restoration</i> , <b>2020</b> , 33,   | 3    | 1 |
| 27 | Barrett's Esophagus <b>2019</b> , 279-290.e5   |      | 1 |

|    |   |      |   |
|----|---|------|---|
| 26 | Management of early-stage esophageal neoplasia (MESEN) consensus. <i>World Journal of Surgery</i> , <b>2014</b> , 38, 96-105  | 3-3  | 1 |
| 25 | Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , <b>2015</b> , 44, xiii  | 4-4  | 1 |
| 24 | Gastroparesis. <i>Gastroenterology Clinics of North America</i> , <b>2015</b> , 44, xiii  | 4-4  | 1 |
| 23 | Radiofrequency ablation for Barrett's esophagus. <i>Current Opinion in Gastroenterology</i> , <b>2014</b> , 30, 415-21  | 3    | 1 |
| 22 | Eosinophilic esophagitis. <i>Gastroenterology Clinics of North America</i> , <b>2014</b> , 43, xiii   | 4-4  | 1 |
| 21 | Antireflux therapy in asthma: is there any role?. <i>Gastroenterology</i> , <b>2009</b> , 137, 1844-6   | 13-3 | 1 |
| 20 | Overestimation of the diagnosis of eosinophilic colitis with reliance on billing codes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 2434-2436 | 5-4  | 0 |
| 19 | Barrett's Esophagus 287-309   |      | 0 |
| 18 | Age of diagnosis in familial Barrett's associated neoplasia. <i>Familial Cancer</i> , <b>2021</b> , 1   | 3    | 0 |
| 17 | The mast cell pain connection in eosinophilic esophagitis.. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2022</b> ,                                     | 9-3  | 0 |
| 16 | Update on ablation for Barrett's esophagus. <i>Current Gastroenterology Reports</i> , <b>2014</b> , 16, 368   | 5    |   |
| 15 | Presentation of the Julius M. Friedenwald Medal to Anil K. Rustgi. <i>Gastroenterology</i> , <b>2017</b> , 152, 2063-2067   | 3-3  |   |
| 14 | Selection of patients for cancer prevention and eradication <b>2015</b> , 209-220   |      |   |
| 13 | Diseases of the Esophagus <b>2012</b> , 874-886   |      |   |
| 12 | Surveillance of Barrett's Esophagus 107-123   |      |   |
| 11 | Antroduodenal manometry. <i>Digestive Diseases and Sciences</i> , <b>1992</b> , 37, 1927  | 4    |   |
| 10 | Update on the use of radiofrequency ablation for treatment of barrett esophagus. <i>Gastroenterology and Hepatology</i> , <b>2013</b> , 9, 447-9                                    | 0-7  |   |
| 9  | Novel Therapeutic Approaches to Eosinophilic Esophagitis. <i>Gastroenterology and Hepatology</i> , <b>2020</b> , 16, 294-301  | 0-7  |   |

|   |   |      |
|---|---|------|
| 8 | Adenocarcinoma in Barrett's Esophagus: Signs, Symptoms and Endoscopic Appearance <b>2001</b> , 291-295  |      |
| 7 | Decision Making in Ablation: Disease, Patients, and Institutional Factors <b>2009</b> , 63-89   |      |
| 6 | Diagnosis and Surveillance of Barrett's Esophagus <b>2012</b> , 321-339   |      |
| 5 | Barrett's Esophagus 509-539   |      |
| 4 | Helicobacter pylori and GERD <b>2021</b> , 419-427  |      |
| 3 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,  | 6.9  |
| 2 | Four Approaches to Reinvigorate Learning for the 21st Century Gastroenterologist. <i>Gastroenterology</i> , <b>2016</b> , 151, 218-21   | 13.3 |
| 1 | Transition of Care from Pediatric to Adult Care in Eosinophilic Esophagitis: Insights From a Patient Perspective Survey. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2021</b> , 73, 722-726 | 2.8  |